Cerus Corp stock (US1570851014): Recent 2.21% gain amid mixed signals

Cerus Corp shares rose 2.21% to $1.39 on July 25, 2025, on Nasdaq, supported by moving averages but facing short-term sell signals.

Cerus Corp stock climbed 2.21% on the last trading day, Friday, July 25, 2025, moving from $1.36 to $1.39 on Nasdaq, according to StockInvest.us as of July 28, 2025. The gain comes amid buy signals from short- and long-term moving averages, though the overall evaluation remains negative with a sell candidate score of -1.627.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Cerus Corporation
• Sector/industry: Medical Devices
• Headquarters/country: United States
• Core markets: Blood safety systems
• Home exchange/listing venue: Nasdaq (CERS)
• Trading currency: USD

Cerus Corp: core business model

Cerus Corporation develops and markets the INTERCEPT Blood System to enhance blood safety by inactivating pathogens in platelets and plasma. The technology targets hospitals, blood banks, and plasma fractionators globally, with a focus on preventing transfusion-transmitted infections. US investors track Cerus for its role in the medical device sector amid rising demand for blood safety solutions.

Main revenue and product drivers for Cerus Corp

Key revenue stems from sales of disposable kits for the INTERCEPT System, used in platelet and plasma processing. In recent periods, the company has expanded into emerging markets, supporting growth. The stock's listing on Nasdaq provides US retail investors direct access to these developments in blood component pathogen inactivation.

Industry trends and competitive position

The medical devices industry sees growth in blood safety technologies, driven by global transfusion needs and pathogen risks. Cerus Corp holds a niche in pathogen reduction systems, competing with limited direct rivals. For US investors, exposure comes via Nasdaq trading and potential FDA-related advancements.

Conclusion

Cerus Corp stock showed a 2.21% increase to $1.39 on July 25, 2025, amid mixed technical signals including buy indications from moving averages but an overall sell rating. The company continues focusing on its INTERCEPT Blood System for blood safety. Investors monitor volume support at $1.34 and resistance levels ahead.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.